Back

Impact of different dose reduction criteria on dose assignment of current DOACs and related outcomes: an analysis from 4-year data of the ETNA-AF Europe programme

8 April 2024 (08:30 - 09:15)
Organised by: Logo
Congress Presentation Part of: Atrial fibrillation: treatment 1 Oral Anticoagulation EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Associate Professor Igor Diemberger

Institute of Cardiology University of Bologna, Bologna (Italy)

7 More presentations in this session

Presentation thumbnail
Effectiveness of photoplethysmography-based rhythm monitoring after atrial fibrillation ablation using a smartphone application
Doctor H. Gruwez (Leuven, BE)
Abstract Slides Video
Presentation thumbnail
Safety and efficacy of long-term sodium channel blocker therapy for early rhythm control: the EAST-AFNET 4 trial
Doctor A. Rillig (Hamburg, DE)
Abstract Slides Video
Presentation thumbnail
Predicting bleeding risk in frail older patients with atrial fibrillation using data from the FRAIL-AF trial
Doctor S. van Doorn (Utrecht, NL)
Abstract Slides Video
Presentation thumbnail
Management of edoxaban therapy in patients undergoing emergency/urgent procedures: a subanalysis of the global, prospective, observational, multinational EMIT-AF/VTE programme
Professor C. Von Heymann (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Difference between cryoballoon and radiofrequency ablations for atrial fibrillation based on electroanatomical mechanisms
Doctor M. Kim (Yongin, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial fibrillation: treatment 1

The Event

Event poster

EHRA 2024

8 April 2024 08:30 CET
You may be interested in
thumbnail
Congress Presentation
From prescription to outcome: real-world utilization of direct oral anticoagulants in atrial fibrillation across Europe
thumbnail
Congress Presentation
AF patients in routine practice: a long-term perspective from ETNA-AF-Europe
thumbnail
Congress Presentation
Low rates of haemorrhagic stroke, not increased by age, renal/hepatic impairment, concomitant anti-platelet use and high CHA2DS2-VASc scores, in the 4-year follow-up of ETNA-AF-Europe

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources